On June 10, 2015 Curis reported that data for CUDC-907 will be presented at the 20th Congress of the European Hematology Association (EHA) (Free EHA Whitepaper), being held from June 11 – June 14, 2015 in Vienna, Austria as well as at the 13th International Congress on Malignant Lymphoma (ICML), being held from June 17 – June 20, 2015 in Lugano, Switzerland (Press release, Curis, JUN 10, 2015, View Source [SID:1234505383]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Curis and its study investigators will present data from the Phase 1 study of CUDC-907, Curis’ proprietary oral, dual histone deacetylase (HDAC) and phosphoinositide 3-kinase (PI3K) inhibitor that is being studied in the ongoing expansion stage of a Phase 1 trial, with a focus on patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The U.S. FDA recently granted Orphan Drug Designation to CUDC-907 for the treatment of DLBCL.
Additional information on the presentations can be found below.
CUDC-907 Presentations:
20th Congress of EHA (Free EHA Whitepaper):
Date/Time: Friday, June 12, 2015, 17:15 – 18:45 CEST
Abstract Number: P325 (Poster)
Presentation Title: A Phase 1 trial of CUDC-907, an oral, first-in-class, dual inhibitor of HDAC and PI3K, in patients with refractory or relapsed lymphoma and multiple myeloma.
Presenter: Jaye Viner, MD
13- ICML:
Date/Time: Thursday, June 18, 2015, 15:35 – 16:55 CEST (Session 6)
Abstract No: 080 (Oral)
Presentation Title: A first-in-human trial of CUDC-907, an oral, first-in-class, dual inhibitor of HDAC and PI3K, in patients with refractory/ relapsed lymphoma and multiple myeloma.
Presenter: Anas Younes, MD